Fluoguide continued its track record of good cost control in Q4, and reported remaining cash and ST investments of DKK 79m, giving it runway well into 2027. Fluoguide submitted its US IND application for FG001 in Q1, on schedule, approval of which which would enable clinical development in the US. We reiterate our SEK 101-117 per share valuation range.
LÄS MER
